LB-102 — Topline data
H1 2027
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027Source filing
LBRX biotech catalysts & pipeline
LB PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
LB-102 — FDA meeting
H2 2027
The Company expects to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027.Source filing
LB-102 — Topline data
Q1 2028
The Phase 2 ILLUMINATE-1 trial evaluating the efficacy and safety of LB-102 in patients with bipolar 1 depression is enrolling patients, with topline data expected in the first quarter of 2028.Source filing
LB-102 — Topline data
H1 2029
Initiation of the Phase 2 trial in the adjunctive treatment of MDD is expected in early 2027, with topline data expected in the first half of 2029.Source filing